INTRODUCTION
As a chronic, enduring condition, diabetic macular edema (DME) has a significant burden of low vision and blindness [1] , is difficult to manage, and therapeutic agents providing sustained benefit are needed [2] . While DME was once solely treated with laser therapy, a large number of patients continued to lose vision, despite treatment [3, 4] . Although antivascular endothelial growth factor (anti-VEGF) therapy has become the preferred treatment for the management of DME, it is not effective in all patients, as demonstrated in the RIDE (ClinicalTrials.gov NCT00473382) and RISE Electronic supplementary material The online version of this article (doi:10.1007/s40123-015-0028-0) contains supplementary material, which is available to authorized users.
(ClinicalTrials.gov NCT00473330) clinical trials, where between 58% and 70% of patients gained a best corrected visual acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (EDTRS) letter score of C10 suggesting approximately one-third of patients were insufficiently responsive to anti-VEGF therapy [5] .
Intravitreal steroids, particularly in sustainedrelease implants, can offer a different DME therapeutic strategy, by providing localized delivery of the corticosteroid to maximize its anti-inflammatory, angiostatic and antipermeability effects, as well as minimize risks of systemic toxicity [3] . Currently, no direct comparative data exist for anti-VEGF versus FAc implant therapy in DME unresponsive to other therapies. Here, the authors describe a patient case that provides both direct comparison between anti-VEGF and FAc implant in the fellow eye, and also insight into the relative efficacy of FAc implant over more than 1 year in DME not responding to anti-VEGF therapy. This case has been reported previously, but follow-up was limited to 12 weeks in one eye, without comparison to the anti-VEGF-treated fellow eye [9] .
CASE REPORT
This case is from a 30-year-old patient with type-I diabetes who was diagnosed with DME around 20 years ago. The patient's glycated hemoglobin (HbA1c) was 9.5% and he was receiving insulin therapy. (Fig. 1a) . CMT remained below 330 lm up to month 3 and then increased slightly, measuring 442 lm at month 9 and 372 lm at month 13, still remaining more than 250 lm below baseline CMT (Figs. 1, 2).
Best corrected visual acuity also increased rapidly following FAc implant in the left eye ( Fig. 3 ; Table 1 ) improving from 0.3 at baseline to 0.5 after 1 month. This change was sustained through to month 9, although at month 13 BCVA decreased slightly to 0.4 as a result of cataract formation, which was confirmed by the return of BCVA to 0.5 1 day after phacoemulsification. The macula at this point still remained dry (see Fig. 1f ).
Treatment of the Right Eye
The right eye was treated with a further three injections of ranibizumab before an FAc implant was injected ( In the 7 months prior to FAc implant, BCVA remained B0.5 in the right eye (Table 1) . At 1 and 6 months after FAc implant, BCVA had increased to 0.6 and 0.7, respectively.
Adverse Events
An increase in intraocular pressure (IOP) was seen in the left eye of the current patient, rising from 20 mmHg at month 3 to 32 mmHg, at month 7. This change was managed with 10 mg brinzolamide/5 mg timolol eye drops which reduced IOP to 16 mmHg. At 13 months, left and right eye IOP (6 months after FAc implant had been administered) was 21 and 18 mmHg, respectively.
No further adverse events have been reported to date, at the time this case study was accepted for publication (January 19, 2015).
DISCUSSION
FAc implant 0.2 lg/day is a second-line therapy indicated for the treatment of vision impairment associated with chronic diabetic macular edema, considered insufficiently responsive to available therapies [8, 10] . In the present case, the patient had not responded The rapid resolution in both edema and BCVA after FAc implant seen in this case (as early as 1 month post-implant) was also seen in the FAME studies (ClinicalTrials.gov NCT00344968) [2] where, in the chronic DME group, central foveal thickness decreased by week 6 and was sustained through to 36 months (Table 1) . During the first 7 months following FAc implant, the left eye showed rapid and marked improvements in BCVA and CMT, which were sustained. In contrast, BCVA did not improve in the right eye, the change in CMT was roughly half that of the left eye, and the macula in the right eye remained swollen and wet (Fig. 1) , which could suggest that in this chronic DME case, anti-VEGF was less effective than FAc implant. This is further 
